Last Updated : May 9, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
Brand Name Sort descending | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
---|---|---|---|---|---|---|
Stribild | Elvitegravir/ Cobicistat/ Emtricitabine/ Tenofovir Disoproxil Fumarate | HIV infection | List with criteria/condition | Complete | ||
Sublinox | Zolpidem tartrate | Insomnia | Do not list | Complete | ||
Sublocade | buprenorphine | Opioid use disorder, treatment | Reimburse with clinical criteria and/or conditions | Complete | ||
Suboxone | Buprenorphine/naloxone | Opioid drug dependence (Substitution treatment) | List with clinical criteria and/or conditions | Complete | ||
Sunvepra | Asunaprevir | Hepatitis C, chronic | Reimburse with clinical criteria and/or conditions | Complete | ||
Sutent | Sunitinib malate | Pancreatic Neuroendocrine Tumour | Reimburse with clinical criteria and/or conditions | Complete | ||
Sutent | Sunitinib | Gastrointestinal stromal tumour (GIST) | List with clinical criteria and/or conditions | Complete | ||
Sutent | Sunitinib malate | Cancer, Metastatic renal cell carcinoma | Do not list | Complete | ||
Sylvant | Siltuximab | Multicentric Castleman's disease (MCD) | Reimburse with clinical criteria and/or conditions | Complete | ||
Symdeko | tezacaftor/ivacaftor | CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer | Not filed |